NEW YORK (GenomeWeb News) – Response Biomedical announced on Thursday a US distribution deal covering its cardiovascular portfolio of Ramp products.

Under the agreement, Louisville, Ky.-based Laboratory Supply Company (LABSCO) will distribute Ramp products in the US exclusively to hospital with less than 150 beds. The agreement is between Response Biomed's newly formed, wholly owned US subsidiary Response Point of Care and LABSCO for an initial period of three years, renewable upon mutual agreement.

Additional terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.